Mibg (123i)

Iobenguane, the active ingredient in Mibg (123i), is a radiopharmaceutical presented as an injectable solution for intravenous use. It is used for imaging of the adrenal medulla, neuroblastoma detection, and evaluation of sympathetic nervous system disorders in patients requiring diagnostic scintigraphy.

GNH USA supplies Mibg (123i) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and clinics worldwide.

Mibg (123i) is a norepinephrine‑analog radiotracer employed in diagnostic imaging of conditions involving adrenergic tissue.

Adrenal medulla imaging (e.g., pheochromocytoma): enables visualization of tumor uptake for diagnosis and surgical planning. Neuroblastoma detection and staging: helps locate primary and metastatic lesions for treatment planning. Sympathetic nervous system disorder evaluation: assesses regional sympathetic activity in diseases such as heart failure or dysautonomia.

Adverse reactions may occur following intravenous administration of Iobenguane.

Common Side Effects: - Nausea or vomiting - Transient flushing or warmth sensation - Mild hypotension or transient hypertension - Headache - Injection‑site pain or bruising - Mild dizziness

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Sustained severe hypotension requiring intervention - Cardiac arrhythmias - Radiation‑induced tissue injury at the injection site - Severe bronchospasm - Persistent neurologic symptoms

Use of Iobenguane requires careful assessment of patient condition and adherence to radiation safety protocols.

Pregnancy: unknown safety; avoid unless essential. Breastfeeding: insufficient data; consider risk‑benefit. Renal impairment: monitor because excretion may be altered. Concomitant drugs affecting norepinephrine transport: may modify tracer uptake. Radiation safety: follow radiopharmacy and institutional guidelines. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane may interact with drugs that influence catecholamine pathways or radiation sensitivity.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: can increase tracer uptake and alter imaging. - Sympathomimetic agents (e.g., epinephrine): compete for NET, reducing image quality. - Beta‑blockers: may modify sympathetic activity and affect scan interpretation.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: monitor blood pressure changes during and after injection. - Chemotherapeutic agents causing marrow suppression: observe for heightened radiation sensitivity.